Data gathered: December 21
AI Stock Analysis - Amgen (AMGN)
Analysis generated November 26, 2024. Powered by Chat GPT.
Amgen Inc. is a leading biotechnology company that develops and manufactures human therapeutics. With a broad portfolio that includes treatments for cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses, Amgen is well-positioned in the biopharmaceutical sector. The company has a strong commitment to research and development, and it currently has multiple products in various stages of development. Amgen operates globally, with a presence in numerous countries, and is headquartered in Thousand Oaks, California.
Stock Alerts - Amgen (AMGN)
 |
Amgen | November 26 Price is down by -10.3% in the last 24h. |
|
Amgen | November 15 Price is down by -5% in the last 24h. |
|
Amgen | November 12 Price is down by -5.8% in the last 24h. |
|
Amgen | November 12 Ro Khanna (member of U.S. congress) is buying shares |
Alternative Data for Amgen
About Amgen
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
| Price | $263.38 |
| Target Price | Sign up |
| Volume | 13,680,000 |
| Market Cap | $140B |
| Year Range | $257 - $334.68 |
| Dividend Yield | 3.64% |
| PE Ratio | 33.32 |
| Analyst Rating | 48% buy |
| Industry | Biotechnology |
In the news
 |
Novo obesity data positive for Eli Lilly and Amgen, says UBSDecember 21 - Yahoo Entertainment |
 |
Amgen (NASDAQ:AMGN) Cut to “Buy” at StockNews.comDecember 20 - ETF Daily News |
 |
What's Going On With Amgen Stock On Friday?December 20 - Biztoc.com |
Novo Crashes 20% After New Obesity Drug Misses Forecasts. Lilly, Viking, Amgen Jump. - Investor's Business DailyDecember 20 - Slashdot.org |
|
 |
Novo Crashes 20% After New Obesity Drug Misses Forecasts. Lilly, Viking, Amgen JumpDecember 20 - Biztoc.com |
 |
Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.December 20 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 8.5B | 6.14B | 2.37B | 2.83B | 5.08B | 5.580 |
| Q2 '24 | 8.52B | 6.22B | 2.3B | 746M | 2.8B | 4.970 |
| Q1 '24 | 6.76B | 6.21B | 548M | -113M | 1.96B | 3.960 |
| Q4 '23 | 7.63B | 6.5B | 1.13B | 767M | 2.77B | 4.710 |
| Q3 '23 | 6.33B | 3.88B | 2.44B | 1.73B | 3.4B | 4.960 |
Insider Transactions View All
| Grygiel Nancy A. filed to sell 9,883 shares at $313.1. May 3 '24 |
| Grygiel Nancy A. filed to sell 10,874 shares at $273. December 4 '23 |
| Graham Jonathan P filed to sell 28,078 shares at $272.8. November 13 '23 |
| Gordon Murdo filed to sell 44,308 shares at $262.4. August 11 '23 |
| Khosla Rachna filed to sell 6,630 shares at $292.9. November 10 '22 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Ro Khanna |
Nov 11, 24 | Buy | $1K - $15K |
| Ro Khanna |
Oct 8, 24 | Buy | $1K - $15K |
| Jared Moskowitz |
Aug 21, 24 | Buy | $1K - $15K |
Read more about Amgen (AMGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Amgen?
The Market Cap of Amgen is $140B.
What is Amgen's PE Ratio?
As of today, Amgen's PE (Price to Earnings) ratio is 33.32.
What is the current stock price of Amgen?
Currently, the price of one share of Amgen stock is $263.38.
How can I analyze the AMGN stock price chart for investment decisions?
The AMGN stock price chart above provides a comprehensive visual representation of Amgen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Amgen shares. Our platform offers an up-to-date AMGN stock price chart, along with technical data analysis and alternative data insights.
Does AMGN offer dividends to its shareholders?
Yes, Amgen (AMGN) offers dividends to its shareholders, with a dividend yield of 3.64%. This dividend yield represents Amgen's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Amgen in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Amgen?
Some of the similar stocks of Amgen are Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.